Cargando…

Cost‐utility analysis of add‐on dapagliflozin in heart failure with reduced ejection fraction in the Philippines

AIM: We aim to determine the cost‐effectiveness of dapagliflozin in addition to standard therapy versus standard therapy alone among patients with heart failure with reduced ejection fraction (HFrEF) using the public healthcare provider's perspective in the Philippines. METHODS AND RESULTS: A t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mendoza, Victor L., Tumanan‐Mendoza, Bernadette A., Punzalan, Felix Eduardo R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712807/ https://www.ncbi.nlm.nih.gov/pubmed/34494399 http://dx.doi.org/10.1002/ehf2.13583

Ejemplares similares

Cost‐utility analysis of add‐on dapagliflozin in heart failure with preserved or mildly reduced ejection fraction
por: Tang, Yi, et al.
Publicado: (2023)

Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction
por: Isaza, Nicolas, et al.
Publicado: (2021)

Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia–Pacific region
por: Liao, Chia-Te, et al.
Publicado: (2021)

Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
por: Chatur, Safia, et al.
Publicado: (2023)

Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?
por: Williams, David M., et al.
Publicado: (2020)

Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction
por: Blair, Hannah A.
Publicado: (2021)

Cost‐effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China
por: Yao, Younan, et al.
Publicado: (2020)

Dapagliflozin and Empagliflozin in Heart Failure with Reduced Ejection Fraction: A Retrospective Study
por: Hao, Zhengyang, et al.
Publicado: (2022)

Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF
por: Jhund, Pardeep S., et al.
Publicado: (2021)

Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
por: Jackson, Alice M., et al.
Publicado: (2020)

Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index
por: Adamson, Carly, et al.
Publicado: (2021)

Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial
por: Vardeny, Orly, et al.
Publicado: (2022)

Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
por: Docherty, Kieran F., et al.
Publicado: (2022)

Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review
por: Mohammadnezhad, Ghader, et al.
Publicado: (2022)

Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
por: Solomon, Scott D., et al.
Publicado: (2021)

Dapagliflozin Impact on the Exercise Capacity of Non-Diabetic Heart Failure with Reduced Ejection Fraction Patients
por: Reis, João, et al.
Publicado: (2022)

Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF
por: Butt, Jawad H., et al.
Publicado: (2021)

Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach
por: Nessler, Jadwiga
Publicado: (2021)

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial
por: Nassif, Michael E., et al.
Publicado: (2021)

Combined treatment with sacubitril/valsartan plus dapagliflozin in patients affected by heart failure with reduced ejection fraction
por: Jiang, Juan, et al.
Publicado: (2023)

Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction
por: Amiguet, Martina, et al.
Publicado: (2023)

Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HF
por: Lewis, Gregory D., et al.
Publicado: (2023)

Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF
por: McEwan, Phil, et al.
Publicado: (2020)

Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF
por: Jhund, Pardeep S., et al.
Publicado: (2020)

Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA‐HF
por: Dewan, Pooja, et al.
Publicado: (2021)

Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
por: Ostrominski, John W., et al.
Publicado: (2022)

Cost–Utility Analysis of Dapagliflozin as an Add-on to Standard of Care for Patients with Chronic Kidney Disease in Thailand
por: Vareesangthip, Kriengsak, et al.
Publicado: (2022)

Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China
por: Tang, Yi, et al.
Publicado: (2022)

Current Treatment of Heart Failure with Preserved Ejection Fraction: Should We Add Life to the Remaining Years or Add Years to the Remaining Life?
por: Li, Jia, et al.
Publicado: (2013)

ADDition of DAPAgliflozin, Sodium-Glucose Cotransporter-2 Inhibitor to Angiotensin Receptor Blocker-Neprilysin Inhibitors Non-Responders in Patient with Refractory Heart Failure with Reduced Ejection Fraction (ADD DAPA trial)
por: Jariwala, Pankaj, et al.
Publicado: (2021)

Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF
por: Docherty, Kieran F., et al.
Publicado: (2020)

Safety and Efficacy of Adding Dapagliflozin to Furosemide in Type 2 Diabetic Patients With Decompensated Heart Failure and Reduced Ejection Fraction
por: Ibrahim, Ayman, et al.
Publicado: (2020)

Direct actions of dapagliflozin and interactions with LCZ696 and spironolactone on cardiac fibroblasts of patients with heart failure and reduced ejection fraction
por: Ortega‐Paz, Luis, et al.
Publicado: (2022)

Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF
por: Yeoh, Su Ern, et al.
Publicado: (2023)

Dapagliflozin Attenuates Heart Failure With Preserved Ejection Fraction Remodeling and Dysfunction by Elevating β-Hydroxybutyrate–activated Citrate Synthase
por: Zhang, Xinxin, et al.
Publicado: (2023)

Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Trial
por: Jhund, Pardeep S., et al.
Publicado: (2023)

Resource utilization and costs among patients with heart failure with reduced ejection fraction following a worsening heart failure event
por: Givertz, Michael M., et al.
Publicado: (2021)

Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction
por: Zhang, Nannan, et al.
Publicado: (2019)

The early effect of dapagliflozin on strain and tissue Doppler parameters of diastolic function in diabetic patients with heart failure with reduced ejection fraction
por: Maragkoudakis, Spyridon, et al.
Publicado: (2021)

Acute pleiotropic effects of dapagliflozin in type 2 diabetic patients with heart failure with reduced ejection fraction: a crossover trial
por: Ilyas, Fahmida, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c0r2l58cegq11pf0ls93l9vasn